PHARMACY BENEFACT

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **June 1, 2023**, updates to the Alberta Drug Benefit List (ADBL) have been posted online at **ab.bluecross.ca/dbl/publications.php**.

Please refer to the June 1, 2023, updates for complete listings of products available by special authorization, changes to criteria for coverage, added products, products with a price change, discontinued products and products removed from the *ADBL*.

Please note that the online interactive Drug Benefit List (iDBL) at **ab.bluecross.ca/dbl/idbl_main1.php** is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for *Alberta Drug*Benefit List (ADBL)

Alberta Blue Cross® has confirmed that the shortage for Auro-Losartan HCT 50 mg/12.5 mg Tablet (DIN 02423642), pms-Losartan-HCTZ 50 mg/12.5 mg Tablet (DIN 02392224) and Sandoz-Losartan HCT 50 mg/12.5 mg Tablet (DIN 02313375) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 7**, **2023**. The following grouping was removed from the Critical Supply Product List **May 5**, **2023**.

LOSARTAN POTASSIUM / HYDROCHLOROTHIAZIDE

50 MG / 12.5 MG TABLET

00002423642	AURO-LOSARTAN HCT	AUR	\$ 0.3146
00002388960	LOSARTAN / HCT	SIV	\$ 0.3146
00002427648	LOSARTAN / HCTZ	SNS	\$ 0.3146
00002389657	MINT-LOSARTAN / HCTZ	MPI	\$ 0.3146
00002392224	PMS-LOSARTAN-HCTZ	PMS	\$ 0.3146
00002313375	SANDOZ-LOSARTAN HCT	SDZ	\$ 0.3146
00002230047	HYZAAR	ORC	\$ 1.4504

continued next page





continued from previous page

Alberta Blue Cross has confirmed that the shortage for Taro-Testosterone Cypionate 100 mg/mL Injection (DIN 02496003) manufactured by Taro Pharmaceutical Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective June 14, 2023. The following grouping was removed from the Critical Supply Product List May 15, 2023.

TESTOSTERONE CYPIONATE

100 MG / ML INJECTION

00002496003	TARO-TESTOSTERONE	TAR	\$ 3.4878
00000030783	DEPO-TESTOSTERONE	PFI	\$ 4.8130

Alberta Blue Cross has confirmed that the shortage for Lorazepam 0.5 mg Sublingual Tablet (DIN 02410745) manufactured by AA Pharma Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective June 16, 2023. The following grouping was removed from the Critical Supply Product List May 17, 2023.

LORAZEPAM

0.5 MG SUBLINGUAL TABLET

00002410745	LORAZEPAM	AAP	\$ 0.0961
00002041456	ATIVAN	PFI	\$ 0.1321

Alberta Blue Cross has confirmed that the shortage for Lorazepam 1 mg Sublingual Tablet (DIN 02410753) manufactured by AA Pharma Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective June 16, 2023. The following grouping was removed from the Critical Supply Product List May 17, 2023.

LORAZEPAM

1 MG SUBLINGUAL TABLET

00002410753	LORAZEPAM	AAP	\$ 0.1210
00002041464	ATIVAN	PFI	\$ 0.1661

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) **403-294-4041** (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php





